| Literature DB >> 21146986 |
Heather Tye1, Stephan G Mueller, Juergen Prestle, Stefan Scheuerer, Marcus Schindler, Bernd Nosse, Natacha Prevost, Christopher J Brown, Alexander Heifetz, Clemens Moeller, Anna Pedret-Dunn, Mark Whittaker.
Abstract
The discovery of a novel series of 5-HT(2C) agonists based on a tricyclic pyrazolopyrimidine scaffold is described. Compounds with good levels of in vitro potency and moderate to good levels of selectivity with respect to the 5-HT(2A) and 5-HT(2B) receptors were identified. One of the analogues (7 g) was found to be efficacious in a sub-chronic weight loss model. A key limitation of the series of compounds was that they were found to be potent inhibitors of the hERG ion channel. Some compounds, bearing polar side chains were identified which showed a much reduced hERG liability however these compounds were sub-optimal in terms of their in vitro potency or selectivity.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21146986 DOI： 10.1016/j.bmcl.2010.11.089
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823